Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

NovImmune Successfully Completes NI-0801 Phase I Clinical Study
NovImmune, an immunology-focused biotech company

No Change In Pharmacokinetics Of ADHD Medication VYVANSE CII When Coadministered With Prilosec
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of Prilosec OTC with ADDERALL XR resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of amphetamine, the active medication. Other pharmacokinetic parameters (maximum plasma concentration and area under curve) of active medication were not altered for either VYVANSE or ADDERALL XR when coadministered with Prilosec OTC. This study, which is the first to evaluate the pharmacokinetics of VYVANSE and ADDERALL XR taken alone and with Prilosec OTC 40 mg, was recently presented at the International Congress on Clinical Pharmacy, co-sponsored by the American College of Clinical Pharmacy (ACCP), in Orlando, FL.
News of the day
Olanzapine Long-Acting Injection (LAI) Efficacy And Safety Data Presented At American Psychiatric Association Annual Meeting
Eli Lilly and Company presented data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder. Olanzapine LAI is an investigational formulation that combines the atypical antipsychotic Zyprexa(R) (olanzapine) with pamoic acid, allowing for the sustained delivery of olanzapine for up to four weeks.
Sexual Health

Some Black Women With Advanced Breast Cancer Opt Against Treatment, Study Finds

A new study has found that some black women with advanced breast cancer declined treatment with chemotherapy or radiation, though researchers did not know the reason why so many of the women opted against treatment, HealthDay/Las Vegas NOW reports. For the study, researchers examined records for 107 women with cases of advanced breast cancer that were reported at one inner-city hospital between 2000 and 2006. Eighty-seven percent of the women were black, and 29% of them had breast cancer tumors that did not respond well to new, targeted treatments. Of all women, 20.5% declined chemotherapy and 26.3% opted against radiation.Lead researcher Monica Rizzo, an assistant professor of surgery at the Division of Surgical Oncology at the Emory University School of Medicine, said the reason why the women declined treatment is not clear, adding, "We looked at marital status, as well as religious background, of those women, and unfortunately, we were not able to find any clear identifier." Researchers speculated that fear of the medical system, poverty and cultural differences might play a role. Rizzo"s group has started a community outreach program through which a nurse practitioner and social worker follow up with breast cancer patients (Reinberg, HealthDay/Las Vegas NOW, 5/22). An abstract of the study is available online. Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009